Hahn v. United States

313 F. App'x 582
CourtCourt of Appeals for the Fourth Circuit
DecidedNovember 5, 2008
Docket07-1343
StatusUnpublished
Cited by9 cases

This text of 313 F. App'x 582 (Hahn v. United States) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fourth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Hahn v. United States, 313 F. App'x 582 (4th Cir. 2008).

Opinion

Affirmed by unpublished opinion. Judge GREGORY wrote the opinion, in which Chief Judge WILLIAMS and Senior Judge CACHERIS joined.

Unpublished opinions are not binding-precedent in this circuit.

GREGORY, Circuit Judge:

The Appellant, Bertram Hahn (“Hahn”), appeals the district court’s decision to dismiss his Federal Tort Claims Act (“FTCA”) lawsuit against the United States. Hahn had initially filed an administrative complaint with the Department of the Army Claims Services (“DACS”) and the Department of the Navy Claims Services (“DNCS”), alleging that he had received negligent medical treatment. Hahn’s claim was denied by DACS on the ground that Hahn had failed to file an administrative complaint within two years after the claim accrued, as required by 28 U.S.C. § 2401(b) (2000). Hahn subsequently filed the instant lawsuit. Upon motion by the United States, the district court dismissed Hahn’s complaint for lack of subject matter jurisdiction, relying on the same ground as DACS.

Because Hahn should have known of the existence and likely cause of his injury more than two years before he filed his administrative complaint, we affirm the decision of the district court.

I.

On May 17, 2000, Hahn went to the emergency room at Bethesda National Naval Medical Center (“BNNMC”) complaining of severe weakness in the limbs. Medical personnel at BNNMC diagnosed Hahn as having Guillain-Barré Syndrome (“GBS”), an acute auto-immune neurological disorder. The medical personnel at BNNMC ordered that Hahn receive intravenous immunoglobulin (“IVIg”) treatment for five days. Later that day, Hahn was transferred to Walter Reed Army Medical Center (“WRAMC”), where his diagnosis and course of treatment were confirmed. Medical personnel at WRAMC began IVIg treatment on May 18, 2000. That same day, Hahn was transferred back to BNNMC and admitted to an intensive care unit with orders to continue the five days of IVIg treatment. According to Hahn, medical personnel at BNNMC failed to follow these instructions and only administered IVIg treatment for one more day. At that time, Hahn was unaware that he was scheduled to receive five days of IVIg treatment. Hahn remained in the intensive care unit at BNNMC until May 21, 2000, when he was transferred to the medical ward at BNNMC. On May 23, 2000, Hahn was transferred to the rehabilitation ward at WRAMC, where he remained until his discharge in June 2001.

After Hahn was discharged from WRAMC, he continued to suffer from residual weakness. Hahn had been told that some GBS patients continue to have residual weakness after receiving treatment. *584 Nevertheless, Hahn consulted with several other doctors regarding further rehabilitation because he was dissatisfied with his level of recovery. Hahn acknowledges that he began receiving consultations from these other doctors in June 2001. (Supp. J.A. 21.) According to Hahn, these doctors asked him whether he had been given any subsequent IVIg treatments or whether he had been given a plasma exchange following the initial IVIg treatment. Hahn answered these questions in the negative, after which the doctors either responded by saying “Oh?” or remained completely silent. (Supp. J.A. 90.)

In August 2003, Hahn met with Dr. Jay Meythaler regarding enrollment in a clinical drug trial for treatment of GBS. Although the initial meeting with Dr. Meyth-aler was similar in many respects to Hahn’s prior consultations, this consultation differed crucially because Hahn provided Dr. Meythaler with his medical records as part of the assessment for the clinical drug trial. Three days after receiving these medical records, Dr. Meyth-aler advised Hahn that BNNMC medical personnel had failed to administer the full five days of IVIg treatment and that this failure may have caused his residual weakness.

On February 26, 2004, Hahn filed an administrative complaint with DACS and DNCS. Hahn’s claim was denied by DACS on February 1, 2006. On April 19, 2006, Hahn filed this lawsuit against the United States under the FTCA, 28 U.S.C. §§ 2671-2680 (2000), in the United States District Court for the District of Columbia. Upon motion by the United States, the court transferred the case to the United States District Court for the District of Maryland. The United States then filed a motion to dismiss the complaint for lack of subject matter jurisdiction because Hahn had failed to bring his administrative complaint within two years after the claim accrued, as required by 28 U.S.C. § 2401(b). The district court granted the motion to dismiss. Hahn appeals.

II.

Hahn contends that the district court erred in granting the motion to dismiss for lack of subject matter jurisdiction because his claim did not accrue until August 2003, when Dr. Meythaler told Hahn that his residual weakness may have been caused by his medical treatment. We review de novo the district court’s grant of a motion to dismiss for lack of subject matter jurisdiction under Rule 12(b)(1) of the Federal Rules of Civil Procedure. Richmond, Fredericksburg & Potomac R.R. Co. v. United States, 945 F.2d 765, 768-69 (4th Cir.1991). When deciding a 12(b)(1) motion, “the district court is to regard the pleadings’ allegations as mere evidence on the issue, and may consider evidence outside the pleadings without converting the proceeding to one for summary judgment.” Id. at 768. The party asserting subject matter jurisdiction has the burden of proving that the court has jurisdiction over the case. Adams v. Bain, 697 F.2d 1213, 1219 (4th Cir.1982). “Unlike the procedure in a 12(b)(6) motion where there is a presumption reserving the truth finding role to the ultimate factfinder, the court in a 12(b)(1) hearing weighs the evidence to determine its jurisdiction.” Id.

As a sovereign, the United States is immune from suit unless it consents to being sued. United States v. Sherwood, 312 U.S. 584, 586, 61 S.Ct. 767, 85 L.Ed. 1058 (1941). When the United States consents to suit for a class of cases, the terms of its consent circumscribe the court’s jurisdiction to entertain a particular suit. Id. at 586-87, 61 S.Ct. 767. Congress created such a limited waiver of sovereign immunity in enacting the FTCA. See 28 U.S.C. §§ 2671-2680. Under the FTCA, *585 the United States consents to suit for injuries caused by the negligent acts or omissions of government employees acting within the scope of their official employment. 28 U.S.C. § 2674; Gould v. U.S. Dep’t of Health & Human Servs.,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Smith v. United States
W.D. Virginia, 2024
Phillips v. United States
E.D. Missouri, 2021
Shahin v. United States
D. Maryland, 2021
Glenn v. Mataloni
M.D. Pennsylvania, 2020
Harriot v. United States
D. South Carolina, 2020
Zander v. United States
843 F. Supp. 2d 598 (D. Maryland, 2012)
Bohrer v. City Hospital, Inc.
681 F. Supp. 2d 657 (N.D. West Virginia, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
313 F. App'x 582, Counsel Stack Legal Research, https://law.counselstack.com/opinion/hahn-v-united-states-ca4-2008.